Novavax’s Covid-19 Vaccine Backed by FDA Advisers

Vaccine experts advising the Food and Drug Administration endorsed Novavax Inc.’s Covid-19 vaccine, voting overwhelmingly that the shot’s benefits outweighed its risks. The outside panel’s 21-0 vote, with one abstention, on Tuesday moves the shot one step closer to becoming available in the U.S. The FDA must next make a decision on authorizing the vaccine, after months of manufacturing-related delays and an agency review that found the shots effective but raised a safety concern. An FDA decision could take weeks. FDA staff said, in their review of Novavax’s application, that the agency must sign off on the company’s latest manufacturing processes.